公开(公告)号：US20240317866A1

公开(公告)日：2024-09-26

申请号：US18216026

申请日：2023-06-29

Applicant: Janssen Biotech, Inc.

Inventor： Joshua Curtin ,  Roland Knoblauch ,  Meena Thayu

IPC: C07K16/28 ,  A61K9/00 ,  A61K39/00 ,  A61K45/06 ,  A61P35/00

CPC classification number: C07K16/2863 ,  A61K9/0019 ,  A61K45/06 ,  A61P35/00 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/31 ,  C07K2317/565

Abstract: The present disclosure provides methods of treating gastric or esophageal cancer in a subject in need thereof by administering a therapeutically effective amount of a bispecific anti-epidermal growth factor receptor (EGFR)/hepatocyte growth factor receptor (c-Met) antibody.

公开(公告)号：US20220372581A1

公开(公告)日：2022-11-24

申请号：US17747346

申请日：2022-05-18

Applicant: Janssen Biotech, Inc.

Inventor： Joshua Curtin

IPC: C12Q1/6886 ,  C07K16/28 ,  A61K39/395 ,  A61K31/5377 ,  G01N33/574 ,  A61P35/00

Abstract: The present disclosure provides methods and kits for determining whether a cancer in a subject is susceptible to a treatment with a combination therapy comprising a bispecific anti-epidermal growth factor receptor (EGFR)/hepatocyte growth factor receptor (c-Met) antibody and an EGFR tyrosine kinase inhibitor (TKI). The present disclosure also provides methods for treating a cancer in a subject based on the susceptibility of the cancer to the treatment with a combination therapy comprising a bispecific EGFR/c-Met antibody and an EGFR TKI.